Metabolite profiling of novel psychoactive substances is critical for documenting drug consumption. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA) is an emerging synthetic cannabinoid whose toxicological and metabolic knowledge are presently unavailable. We aimed to determine optimum markers for identifying ADB-FUBINACA consumption. Metabolic stability was evaluated with human liver microsome
